Mostrando 83,981 - 84,000 Resultados de 84,353 Para Buscar '"HR"', tiempo de consulta: 0.56s Limitar resultados
  1. 83981
    “…INTRODUCTION: Burn shock resuscitation fluids should be titrated to achieve a urine output (UOP) of 0.5 to 1 mL/kg/hr. It is unknown whether this UOP goal should be indexed to actual body weight (ABW) or predicted body weight (PBW). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  2. 83982
    “…MiR-146a rs2910164 polymorphism in dominant model was associated with the incidence of MACE in post-PCI patients (CG + GG vs. CC, HR = 1.405, 95% CI (1.018–1.939), P = 0.038). However, the miR-34b rs4938723 polymorphism was not associated with the prevalence and prognosis of ACS. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  3. 83983
  4. 83984
  5. 83985
    “…Following parameters were analysed: 1. in ECG: mean heart rate (mHR); PQ interval (PQ), QRS duration (QRSd); corrected QT interval (QTc); atrial fibrillation (AF); inappropriate sinus tachycardia (ITS), QRS duration > 120ms (QRS>120); LBBB, RBBB, QRS fragmentation (QRSf); STT wave abnormalities (STTabn); presence of premature supraventricular (SVES) and ventricular (VES) complexes; 2. in 24-h Holter ECG: sinus tachycardia (STach), new atrial fibrillation (AFHolter), SVES > 1000/24h (SVES>1000); supraventricular tachycardia (TSV), VES > 1000/24h (VES>1000), Couplet VES (VEScouplet), non-sustained ventricular tachycardia (nsVT); ventricular tachycardia (VT), block A-V 2nd typ 2 and/or block A-V 3rd grade (AVdist). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  6. 83986
    “…Following parameters were analysed in ECG: mean heart rate (mHR); PQ interval (PQ), QRS duration (QRSd); corrected QT interval (QTc); atrial fibrillation (AF); inappropriate sinus tachycardia (ITS), QRS duration > 120ms (QRS>120); LBBB, RBBB, QRS fragmentation (QRSf); STT wave abnormalities (STTabn); presence of premature supraventricular (SVES) and ventricular (VES) complexes; in 24-h Holter ECG: sinus tachycardia (STach), new atrial fibrillation (AFHolter), SVES > 1000/24h (SVES>1000); supraventricular tachycardia (TSV), VES > 1000/24h (VES>1000), Couplet VES (VEScouplet), non-sustained sustained tachycardia (nsVT); ventricular tachycardia (VT), block A-V 2nd typ 2 and/or block A-V 3rd grade (AVdist). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  7. 83987
    “…Cox-regression demonstrated a significant independent association of myocardium-total enhancement interface with an event (HR 2.79; 1.44-5.44, p < .01). Kaplan-Meier analysis showed a significantly higher event rate in patients with an interface area between myocardium-total enhancement of more than 72cm2 (Figure 1A) and BZ-core more than 42.3cm2 (Figure 1B). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  8. 83988
    “…There were no differences in neither device-associated complications requiring revision (15.0 vs. 19.1%, p=0.52), nor in all-cause mortality (3.7 vs. 1.9%, p=0.52; HR 0.5, 95%CI: 0.06-4.27) after 1-year of follow-up, but female patients had a higher mean number of rehospitalizations (1.6±1.5 vs. 2.1±1.3; p=0.026). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  9. 83989
    “…The 6MWD was measured for all patients before surgery. e[Formula: see text] O(2max) was calculated using the regression model of Burr, which uses 6MWD, age, gender, weight, and resting heart rate (HR) to predict aerobic fitness. The patients were categorized into PPC and non-PPC group. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  10. 83990
    “…The expression of ASPA was found to be significantly down-regulated in PCa tissue samples, and its decreased expression was independently associated with patients’ prognosis (HR = 0.60, 95% CI 0.40–0.92, P = 0.018). Our experiments demonstrated that modulation of ASPA activity, either through gain- or loss-of-function, led to the suppression or enhancement of PCa cell proliferation, migration, and invasion, respectively. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  11. 83991
    “…Multivariable analysis showed that participants aged 19 years and older were almost twice as likely to seroconvert during the study period compared with those aged 10 to 18 years (Hazard ratio: HR = 1.7 [1.3–2.3], p < 0.001). Those aged 10–18 years exhibited more asymptomatic forms than those aged 19 years and older, among those who achieved seroconversion (72.9% vs. 40.4%, p < 0.001). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  12. 83992
    “…Threshold analysis indicated a sharply increased risk of mortality in participants whose sleep exceeds 9 h (HR = 1.20, 95%CI: 1.11, 1.30). CONCLUSION: Compared with the persistent sleep trajectory of 7 h, moderately and rapidly increased sleep duration trajectories were associated with higher subsequent mortality in Chinese elderly. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  13. 83993
  14. 83994
    “…Compared with the no admissions group, mortality was highest in the recently high admissions group (post-hospital mortality HR 2·70 [95% CI 2·35–2·81]; p<0·0001) and the risk of readmission was highest in the persistently high admissions group (3·23 [2·89–3·61]; p<0·0001). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  15. 83995
  16. 83996
    “…While in the population with increased hs-CRP, only ApoAI > 2.10 g/L had a significant association with CVD [HR (95% CI): 1.69 (1.14–2.51)]. Interaction analyses showed that increased hs-CRP had multiplicative and additive interactions with LDL-C ≥ 160 mg/dL and non-HDL-C ≥ 190 mg/dL on the risk of CVD [HRs (95%CIs): 0.309 (0.153–0.621), and 0.505 (0.295–0.866); RERIs (95%CIs): -1.704 (-3.430-0.021 and − 0.694 (-1.476-0.089), respectively, all P < 0.05]. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  17. 83997
    “…In the QUAZAR AML-001 trial, oral azacitidine significantly improved overall survival (OS) versus placebo: median OS gain of 9.9 months (24.7 months versus 14.8 months; hazard ratio (HR) 0.69 (95% CI 0.55–0.86), p < 0.001). The median time to relapse was also better for oral azacitidine, and the incidences of TEAEs were similar for the two arms. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  18. 83998
  19. 83999
    por Bersanelli, Melissa, Verzoni, Elena, Cortellini, Alessio, Giusti, Raffaele, Calvetti, Lorenzo, Ermacora, Paola, Di Napoli, Marilena, Catino, Annamaria, Guadalupi, Valentina, Guaitoli, Giorgia, Scotti, Vieri, Mazzoni, Francesca, Veccia, Antonello, Guglielmini, Pamela Francesca, Perrone, Fabiana, Maruzzo, Marco, Rossi, Ernesto, Casadei, Chiara, Montesarchio, Vincenzo, Grossi, Francesco, Rizzo, Mimma, Travagliato Liboria, Maria Grazia, Mencoboni, Manlio, Zustovich, Fable, Fratino, Lucia, Accettura, Caterina, Cinieri, Saverio, Camerini, Andrea, Sorarù, Mariella, Zucali, Paolo Andrea, Ricciardi, Serena, Russo, Antonio, Negrini, Giorgia, Banzi, Maria Chiara, Lacidogna, Gaetano, Fornarini, Giuseppe, Laera, Letizia, Mucciarini, Claudia, Santoni, Matteo, Mosillo, Claudia, Bonetti, Andrea, Longo, Lucia, Sartori, Donata, Baldini, Editta, Guida, Michele, Iannopollo, Mauro, Bordonaro, Roberto, Morelli, Maria Francesca, Tagliaferri, Pierosandro, Spada, Massimiliano, Ceribelli, Anna, Silva, Rosa Rita, Nolè, Franco, Beretta, Giordano, Giovanis, Petros, Santini, Daniele, Luzi Fedeli, Stefano, Nanni, Oriana, Maiello, Evaristo, Labianca, Roberto, Pinto, Carmine, Clemente, Alberto, Tognetto, Michele, De Giorgi, Ugo, Pignata, Sandro, Di Maio, Massimo, Buti, Sebastiano, Giannarelli, Diana
    Publicado 2023
    “…The multivariable analyses confirmed the favourable impact of influenza vaccination in terms of OS (HR 0.75, 95% C.I. 0.62–0.92; p = 0.005) and DCR (OR 1.47, 95% C.I. 1.11–1.96; p = 0.007). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  20. 84000
    “…Patients receiving alectinib versus crizotinib as their first ALK TKI treatment experienced significantly prolonged median rwPFS (29.3 versus 10.4 months) with an HR of 0.38 (95% CI 0.21–0.67), while prolonged median mAEFS (not reached versus 91.3 months) and OS (54.1 versus 45.8 months) were observed in patients receiving alectinib versus crizotinib but did not reach statistical significance. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
Herramientas de búsqueda: RSS